# Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

> **NCT04179084** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Metastasis Colorectal Cancer

## Interventions

- **DRUG:** fruquintinib
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04179084
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-28
- **Primary completion:** 2020-03-01
- **Final completion:** 2020-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179084, "Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04179084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*